<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">
Skip to content

HTA direction and implementation tools for the future of health care decisions (LiveSLR & LiveNMA)

 

In response to the recent increase in speed of scientific evidence generation and expanded use of real-world data, healthcare decision-making bodies are searching for new ways to implement more responsive, innovative processes for the technologies’ assessment. These changes along the increased recognition of current HTA challenges (amount of new evidence combined with insufficient speed of current evidence generation methods) have opened a window of opportunity for decision makers to consider moving towards a fully, “living” approach to health technology assessment (HTA). 

The first webinar in the series looks to draw the following key learnings:

  • Discuss HTA trends toward exploration of more reactive and flexible “liveHTA” approaches
  • Demonstrate available tools: LiveSLR and LiveNMA as potential parts of the future liveHTA reality for health care decision-makers. 

 

Download Slides

 

Anna Forsythe

Prior to joining Cytel, Anna Forsythe cofounded PSE with the vision of providing curated evidence and economic modeling to support global HTA. Anna maintains close partnerships to ensure continuous alignment with the client’s strategic objectives. She capitalizes on her insights developed over more than two decades in global product commercialization, strategic drug development, market access, HEOR, and pricing and reimbursement. Anna’s most recent role was Executive Director and Head of Global Value and Access Strategy at Eisai. A thought leader in HEOR, Anna is an adjunct health economics professor at Long Island University College of Pharmacy, a guest lecturer at Rutgers University Business School, and a frequent contributor to forums, articles, and conferences addressing healthcare value and access. In addition to her PharmD and MBA, Anna earned a MS in Health Economics and Public Policy from the University of Birmingham.

 

Grammati Sarri

Grammati worked in private consultancies leading HEOR projects and providing strategic guidance on evidence synthesis and clinical effectiveness analyses for early product value demonstration and HTA submissions. Grammati has gained RWE expertise on leveraging this data for health care decision making through her ISPE leading role in producing guidance documents (such as developing a RWE framework for combining evidence from different sources (work recognized by NICE, EU HTx project), using electronic health records (for COVID-19) and ongoing collaborations with key stakeholders (Harvard Medical School, Utrecht University, NICE). Grammati has also a strong experience in understanding the payer perspective and requirements through her senior leadership role in the development of NICE Guidelines and closely working with clinicians, patient's and NICE executives.

 

Contact Us

Fill in the form below to get in touch